23andMe will use the funding to research genetic factors underlying responses to three drug classes — non-steroidal anti-inflammatory drugs, protein-pump inhibitors used to treat gastroesophogeal reflux disease, and the blood thinner warfarin.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.